SlideShare ist ein Scribd-Unternehmen logo
1 von 26
Tuberculosis treatment: general principles and approach Lecturer: Ph.D M.G.Dolynska
Historical background ,[object Object],[object Object],[object Object],[object Object]
The AIMS of treatment of tuberculosis are: ,[object Object],[object Object],[object Object],[object Object],[object Object]
DOTS ( Directly observed treatment short course ), Karel Styblo, 1972 ,[object Object],[object Object],[object Object],[object Object]
The five elements of the expanded DOTS framework are:   ,[object Object],[object Object],[object Object],[object Object],[object Object]
Dosage and abbreviation of essential antituberculosis drugs 30 (20-35) 15 (15-20) Ethambutol (E) 15 (12-18) 15 (12-18) Streptomycin (S) 35 (30-40) 25 (20-30) Pyrasinamide (Z) 10 (8-12) 10 (8-12) Rifampicin (R) 10 (8-12) 5 (4-6) Isoniasid (H) 3 times weekly Daily Recommended dosage (dose range) in md/kg Drug (abbreviation)
Basical treatment regimens   Optional 5 (HRE) 3 Optional 2(HRZES) 3 /1HRZE 3 Preferred 5 HRE VI Preferred 2 HRZES / 1 HRZE VI Previously treated sputum smearpositive PTB: - relapse; - treatment after default  II Optional 4 (HR)3 or 6 HE V Optional  or 2 (HRZE) 3 or 2 HRZE IV Preferred 4 HR 4 (HR)3 Preferred 2 HRZE I New smear-positive patients; new smear-negative PTB with extensive parenchymal involvement; concomitant HIV disease or severe forms of extrapulmonary TB I Continual phase Initial phase Treatment regimen I TB patients Diagnostic category
Basical treatment regimens (continued) WHO/CDS/TB/2003.313 Treatment of tuberculosis:guidelines  for national programmes, third edition. Revision approved by STAG, June 2004 Specially designed standardized or individualized regimens Chronic (still sputum-positive after supervised re-treatment); proven or suspected MDR TB cases. IV Optional 4 (HR)3 or 6 HE Optional 2 (HRZE)3 Preferred 4 HR Preferred 2 HRZE VIII New smear-negative PTB (other than in category I) and less severe forms of extra-pulmonary TB  III Continual phase Initial phase Treatment regimen I TB patients Diagnostic category
Criticism concern with the DOTS strategy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Expanded treatment conception ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
Drug resistance   ,[object Object],[object Object],[object Object],[object Object]
Drug resistance ,[object Object],[object Object]
Main resistance types ,[object Object],Resistance mono MDR poly
MDR-TB  prevalence among new cases and countries in which at least one  XDR-TB  case has been reported At the end of  2006  year  XDR-TB  has been detected in 17 countries
Extensively drug resistance (XDR) – main definitions ,[object Object],[object Object]
Second line drugs ,[object Object],[object Object],[object Object]
Classes of second-line antituberculosis drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Classes of second-line antituberculosis drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Classes of second-line antituberculosis drugs ,[object Object],[object Object],[object Object],[object Object],[object Object]
Classes of second-line antituberculosis drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Acceptable regimen for the treatment   of MDR Tuberculosis
[object Object]
Recovery criteria ,[object Object],[object Object],[object Object]
 
TB and HIV treatment sequence

Weitere ähnliche Inhalte

Was ist angesagt?

Recent changes in RNTCP Guidelines
Recent changes in RNTCP Guidelines    Recent changes in RNTCP Guidelines
Recent changes in RNTCP Guidelines Arvind Ghongane
 
Tuberculosis- management and treatment
Tuberculosis- management and treatmentTuberculosis- management and treatment
Tuberculosis- management and treatmentKapil Sharma Neupane
 
Antitubercular drugsnew
Antitubercular drugsnewAntitubercular drugsnew
Antitubercular drugsnewaditimaitra3
 
Treatment of Tuberculosis
Treatment of TuberculosisTreatment of Tuberculosis
Treatment of TuberculosisDr. Amit Anand
 
New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...
New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...
New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...UC San Diego AntiViral Research Center
 
Revised National Tuberculosis Control Program
Revised National Tuberculosis Control ProgramRevised National Tuberculosis Control Program
Revised National Tuberculosis Control ProgramAmol Kinge
 
Multi drug resistant
Multi drug resistantMulti drug resistant
Multi drug resistantHiba Ashibany
 
Newer anti tb drugs
Newer anti tb drugsNewer anti tb drugs
Newer anti tb drugsAnkur Gupta
 
Antibiotics in icu
Antibiotics in icuAntibiotics in icu
Antibiotics in icuimran80
 
Management Of Community Acquired Pneumonia
Management  Of Community Acquired PneumoniaManagement  Of Community Acquired Pneumonia
Management Of Community Acquired PneumoniaAshraf ElAdawy
 
clinical standards for ds tb treatment 2022 (1).pptx
clinical standards for ds tb treatment 2022 (1).pptxclinical standards for ds tb treatment 2022 (1).pptx
clinical standards for ds tb treatment 2022 (1).pptxPathKind Labs
 
Multi drug resistant tuberculosis
Multi drug resistant tuberculosis Multi drug resistant tuberculosis
Multi drug resistant tuberculosis Dr. Ankit Chaudhary
 
Anti tuberculosis therapy ( att)
Anti tuberculosis therapy  ( att)Anti tuberculosis therapy  ( att)
Anti tuberculosis therapy ( att)DrShrey Bhatia
 

Was ist angesagt? (20)

Recent changes in RNTCP Guidelines
Recent changes in RNTCP Guidelines    Recent changes in RNTCP Guidelines
Recent changes in RNTCP Guidelines
 
Tuberculosis- management and treatment
Tuberculosis- management and treatmentTuberculosis- management and treatment
Tuberculosis- management and treatment
 
Antitubercular drugsnew
Antitubercular drugsnewAntitubercular drugsnew
Antitubercular drugsnew
 
Treatment of Tuberculosis
Treatment of TuberculosisTreatment of Tuberculosis
Treatment of Tuberculosis
 
Treatment of Tuberculosis
Treatment of TuberculosisTreatment of Tuberculosis
Treatment of Tuberculosis
 
MDR TB
MDR TB MDR TB
MDR TB
 
New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...
New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...
New Drugs and Novel Approaches to Treatment Shortening for Drug-Susceptible a...
 
Revised National Tuberculosis Control Program
Revised National Tuberculosis Control ProgramRevised National Tuberculosis Control Program
Revised National Tuberculosis Control Program
 
Quinolones and fluoroquinolones
Quinolones and fluoroquinolonesQuinolones and fluoroquinolones
Quinolones and fluoroquinolones
 
Tb treatment new
Tb treatment newTb treatment new
Tb treatment new
 
Multi drug resistant
Multi drug resistantMulti drug resistant
Multi drug resistant
 
Newer anti tb drugs
Newer anti tb drugsNewer anti tb drugs
Newer anti tb drugs
 
Antibiotics in icu
Antibiotics in icuAntibiotics in icu
Antibiotics in icu
 
Management Of Community Acquired Pneumonia
Management  Of Community Acquired PneumoniaManagement  Of Community Acquired Pneumonia
Management Of Community Acquired Pneumonia
 
Latent TB
Latent TBLatent TB
Latent TB
 
clinical standards for ds tb treatment 2022 (1).pptx
clinical standards for ds tb treatment 2022 (1).pptxclinical standards for ds tb treatment 2022 (1).pptx
clinical standards for ds tb treatment 2022 (1).pptx
 
MDR TB ppt.pptx
MDR TB  ppt.pptxMDR TB  ppt.pptx
MDR TB ppt.pptx
 
MDR T.B.
MDR T.B.MDR T.B.
MDR T.B.
 
Multi drug resistant tuberculosis
Multi drug resistant tuberculosis Multi drug resistant tuberculosis
Multi drug resistant tuberculosis
 
Anti tuberculosis therapy ( att)
Anti tuberculosis therapy  ( att)Anti tuberculosis therapy  ( att)
Anti tuberculosis therapy ( att)
 

Andere mochten auch

Treatment of Tuberculosis
Treatment of TuberculosisTreatment of Tuberculosis
Treatment of Tuberculosisakong
 
Tuberculosis slides
Tuberculosis slidesTuberculosis slides
Tuberculosis slidesnandicinta
 
Pharmacotherapy of TUBERCULOSIS
Pharmacotherapy of TUBERCULOSISPharmacotherapy of TUBERCULOSIS
Pharmacotherapy of TUBERCULOSISRahul Kshirsagar
 
Anti tuberculosis drugs
Anti tuberculosis drugsAnti tuberculosis drugs
Anti tuberculosis drugsSidharth Yadav
 
Pulmonary tuberculosis ppt
Pulmonary tuberculosis pptPulmonary tuberculosis ppt
Pulmonary tuberculosis pptUma Binoy
 
WHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis managementWHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis managementDr. Pratyush Kumar
 
Tuberculosis presentation
Tuberculosis presentationTuberculosis presentation
Tuberculosis presentationRRR784
 
General principles in the treatment of TB BY NAHID SHERBINI
General principles in the treatment of TB BY NAHID SHERBINIGeneral principles in the treatment of TB BY NAHID SHERBINI
General principles in the treatment of TB BY NAHID SHERBININahid Sherbini
 
Tuberculosis a brief outlook
Tuberculosis a brief outlookTuberculosis a brief outlook
Tuberculosis a brief outlookRxVichuZ
 
Mdr tb khaled latest
Mdr tb khaled latestMdr tb khaled latest
Mdr tb khaled latestKhaled Hassan
 
Esophageal cancer-role of RT
Esophageal cancer-role of RTEsophageal cancer-role of RT
Esophageal cancer-role of RTBharti Devnani
 
Diagnosis of tuberculosis
Diagnosis of tuberculosisDiagnosis of tuberculosis
Diagnosis of tuberculosisKhaled ezzat
 
Diagnosis of Pulmonary Tuberculosis
Diagnosis of Pulmonary TuberculosisDiagnosis of Pulmonary Tuberculosis
Diagnosis of Pulmonary TuberculosisJack Frost
 
Bioavailability of drug through iv,im
Bioavailability of drug through iv,imBioavailability of drug through iv,im
Bioavailability of drug through iv,imNimra Iqbal
 

Andere mochten auch (20)

Treatment of Tuberculosis
Treatment of TuberculosisTreatment of Tuberculosis
Treatment of Tuberculosis
 
TB treatment
TB treatmentTB treatment
TB treatment
 
Tuberculosis slides
Tuberculosis slidesTuberculosis slides
Tuberculosis slides
 
Pharmacotherapy of TUBERCULOSIS
Pharmacotherapy of TUBERCULOSISPharmacotherapy of TUBERCULOSIS
Pharmacotherapy of TUBERCULOSIS
 
Anti tuberculosis drugs
Anti tuberculosis drugsAnti tuberculosis drugs
Anti tuberculosis drugs
 
Pulmonary tuberculosis..ptt
Pulmonary tuberculosis..pttPulmonary tuberculosis..ptt
Pulmonary tuberculosis..ptt
 
Pulmonary tuberculosis ppt
Pulmonary tuberculosis pptPulmonary tuberculosis ppt
Pulmonary tuberculosis ppt
 
WHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis managementWHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis management
 
Tuberculosis presentation
Tuberculosis presentationTuberculosis presentation
Tuberculosis presentation
 
General principles in the treatment of TB BY NAHID SHERBINI
General principles in the treatment of TB BY NAHID SHERBINIGeneral principles in the treatment of TB BY NAHID SHERBINI
General principles in the treatment of TB BY NAHID SHERBINI
 
Tuberculosis a brief outlook
Tuberculosis a brief outlookTuberculosis a brief outlook
Tuberculosis a brief outlook
 
Mdr tb khaled latest
Mdr tb khaled latestMdr tb khaled latest
Mdr tb khaled latest
 
Esophageal cancer-role of RT
Esophageal cancer-role of RTEsophageal cancer-role of RT
Esophageal cancer-role of RT
 
Diagnosis of tuberculosis
Diagnosis of tuberculosisDiagnosis of tuberculosis
Diagnosis of tuberculosis
 
Principle of mdr tb management
Principle of mdr tb managementPrinciple of mdr tb management
Principle of mdr tb management
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
published paper
published paperpublished paper
published paper
 
C0342010014
C0342010014C0342010014
C0342010014
 
Diagnosis of Pulmonary Tuberculosis
Diagnosis of Pulmonary TuberculosisDiagnosis of Pulmonary Tuberculosis
Diagnosis of Pulmonary Tuberculosis
 
Bioavailability of drug through iv,im
Bioavailability of drug through iv,imBioavailability of drug through iv,im
Bioavailability of drug through iv,im
 

Ähnlich wie Tuberculosis treatment

Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt. Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt. Silajit Dutta
 
MDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem ArifMDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem ArifTASLEEM ARIF
 
Mdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arifMdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arifTASLEEM ARIF
 
WHO GUIDE LINE ON MDR.pptx
WHO GUIDE LINE ON MDR.pptxWHO GUIDE LINE ON MDR.pptx
WHO GUIDE LINE ON MDR.pptxDr Imran Shaikh
 
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENTDRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENTDr.Lalit Kumar
 
Management of mdr tb and role of pharmacist
Management of mdr tb and role of pharmacistManagement of mdr tb and role of pharmacist
Management of mdr tb and role of pharmacistBronson Munsaka
 
Introduction to drugs for tuberculosis and leprosy
Introduction to drugs for tuberculosis and leprosyIntroduction to drugs for tuberculosis and leprosy
Introduction to drugs for tuberculosis and leprosySubramani Parasuraman
 
Treatment of childhood tb
Treatment of childhood tbTreatment of childhood tb
Treatment of childhood tbDr Inayat Ullah
 
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptxUpdated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptxDrKGPiparvaPharmalec
 
Drug therapy for TB
Drug therapy for TBDrug therapy for TB
Drug therapy for TBHINDUJACON
 
Tb seminar by rs
Tb seminar by rsTb seminar by rs
Tb seminar by rsRafi Bhat
 
Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis Amer Alboush
 
Multi drug resistant tuberculosis
Multi drug resistant tuberculosisMulti drug resistant tuberculosis
Multi drug resistant tuberculosisMelaku Yetbarek,MD
 

Ähnlich wie Tuberculosis treatment (20)

Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt. Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt.
 
MDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem ArifMDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem Arif
 
Mdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arifMdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arif
 
WHO GUIDE LINE ON MDR.pptx
WHO GUIDE LINE ON MDR.pptxWHO GUIDE LINE ON MDR.pptx
WHO GUIDE LINE ON MDR.pptx
 
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENTDRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
 
Drugresistanttuberculosis 100227020029 Phpapp01
Drugresistanttuberculosis 100227020029 Phpapp01Drugresistanttuberculosis 100227020029 Phpapp01
Drugresistanttuberculosis 100227020029 Phpapp01
 
Management of mdr tb and role of pharmacist
Management of mdr tb and role of pharmacistManagement of mdr tb and role of pharmacist
Management of mdr tb and role of pharmacist
 
Introduction to drugs for tuberculosis and leprosy
Introduction to drugs for tuberculosis and leprosyIntroduction to drugs for tuberculosis and leprosy
Introduction to drugs for tuberculosis and leprosy
 
1INTRO~1.PPT
1INTRO~1.PPT1INTRO~1.PPT
1INTRO~1.PPT
 
Management of DR-TB
Management of DR-TBManagement of DR-TB
Management of DR-TB
 
Treatment of childhood tb
Treatment of childhood tbTreatment of childhood tb
Treatment of childhood tb
 
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptxUpdated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
 
A case of MDR-TB
A case of MDR-TBA case of MDR-TB
A case of MDR-TB
 
Drug therapy for TB
Drug therapy for TBDrug therapy for TB
Drug therapy for TB
 
Tb seminar by rs
Tb seminar by rsTb seminar by rs
Tb seminar by rs
 
Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis
 
Multi drug resistant tuberculosis
Multi drug resistant tuberculosisMulti drug resistant tuberculosis
Multi drug resistant tuberculosis
 
Mdr xdr TB
Mdr xdr TBMdr xdr TB
Mdr xdr TB
 
MDR-TB
MDR-TBMDR-TB
MDR-TB
 
Multi drug resistant
Multi drug resistantMulti drug resistant
Multi drug resistant
 

Kürzlich hochgeladen

Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Celine George
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designMIPLM
 
Karra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptxKarra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptxAshokKarra1
 
Q4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptxQ4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptxnelietumpap1
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTiammrhaywood
 
Science 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxScience 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxMaryGraceBautista27
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Jisc
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatYousafMalik24
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPCeline George
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersSabitha Banu
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Celine George
 
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...Postal Advocate Inc.
 
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSGRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSJoshuaGantuangco2
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxAnupkumar Sharma
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxthorishapillay1
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Mark Reed
 

Kürzlich hochgeladen (20)

Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17
 
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptxLEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-design
 
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptxYOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptx
 
Karra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptxKarra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptx
 
Q4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptxQ4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptx
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
 
Science 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxScience 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptx
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice great
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERP
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginners
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
 
Raw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptxRaw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptx
 
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
 
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSGRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptx
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)
 

Tuberculosis treatment

  • 1. Tuberculosis treatment: general principles and approach Lecturer: Ph.D M.G.Dolynska
  • 2.
  • 3.
  • 4.
  • 5.
  • 6. Dosage and abbreviation of essential antituberculosis drugs 30 (20-35) 15 (15-20) Ethambutol (E) 15 (12-18) 15 (12-18) Streptomycin (S) 35 (30-40) 25 (20-30) Pyrasinamide (Z) 10 (8-12) 10 (8-12) Rifampicin (R) 10 (8-12) 5 (4-6) Isoniasid (H) 3 times weekly Daily Recommended dosage (dose range) in md/kg Drug (abbreviation)
  • 7. Basical treatment regimens Optional 5 (HRE) 3 Optional 2(HRZES) 3 /1HRZE 3 Preferred 5 HRE VI Preferred 2 HRZES / 1 HRZE VI Previously treated sputum smearpositive PTB: - relapse; - treatment after default II Optional 4 (HR)3 or 6 HE V Optional or 2 (HRZE) 3 or 2 HRZE IV Preferred 4 HR 4 (HR)3 Preferred 2 HRZE I New smear-positive patients; new smear-negative PTB with extensive parenchymal involvement; concomitant HIV disease or severe forms of extrapulmonary TB I Continual phase Initial phase Treatment regimen I TB patients Diagnostic category
  • 8. Basical treatment regimens (continued) WHO/CDS/TB/2003.313 Treatment of tuberculosis:guidelines for national programmes, third edition. Revision approved by STAG, June 2004 Specially designed standardized or individualized regimens Chronic (still sputum-positive after supervised re-treatment); proven or suspected MDR TB cases. IV Optional 4 (HR)3 or 6 HE Optional 2 (HRZE)3 Preferred 4 HR Preferred 2 HRZE VIII New smear-negative PTB (other than in category I) and less severe forms of extra-pulmonary TB III Continual phase Initial phase Treatment regimen I TB patients Diagnostic category
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15. MDR-TB prevalence among new cases and countries in which at least one XDR-TB case has been reported At the end of 2006 year XDR-TB has been detected in 17 countries
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. Acceptable regimen for the treatment of MDR Tuberculosis
  • 23.
  • 24.
  • 25.  
  • 26. TB and HIV treatment sequence